Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis

@article{Nicoar2016RegressionRF,
  title={Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis},
  author={S. Nicoară and A. Ștefănuț and C. Nascutzy and G. Zaharie and L. Toader and T. Drugan},
  journal={Medical Science Monitor : International Medical Journal of Experimental and Clinical Research},
  year={2016},
  volume={22},
  pages={1192 - 1209}
}
Background Retinopathy is a serious complication related to prematurity and a leading cause of childhood blindness. The aggressive posterior form of retinopathy of prematurity (APROP) has a worse anatomical and functional outcome following laser therapy, as compared with the classic form of the disease. The main outcome measures are the APROP regression rate, structural outcomes, and complications associated with intravitreal bevacizumab (IVB) versus laser photocoagulation in APROP. Material… Expand
Supplemental Laser for Eyes Treated with Bevacizumab Monotherapy in Severe Retinopathy of Prematurity.
TLDR
In this small series, the proposed protocol of IVB monotherapy with deferred laser treatment can be used in severe ROP patients with poor compliance and devastating complications and associated blindness related to reactivation of the disease were not seen. Expand
Intravitreal bevacizumab injection in aggressive posterior retinopathy of prematurity compared with type I retinopathy of prematurity
TLDR
Bilateral eye involvement, relapse and retreatment (IVB, laser and surgical intervention) are more frequent in AP-ROP than type I ROP even when treated with intravitreal bevacizumab injection. Expand
Therapeutic Options in Retinopathy of Prematurity
TLDR
Intravitreal anti-VEGF proved its superiority in treating APROP as compared to laser, with no systemic and/or local side effects in the authors' series. Expand
Complications of retinopathy of prematurity treatment
TLDR
Complications of treatment for retinopathy of prematurity (ROP) and compare complications of laser and intravitreal antivascular endothelial growth factor (VEGF) injections are summarized to establish comparative risks of neurodevelopmental complications. Expand
Aggressive posterior retinopathy of prematurity: a review on current understanding
TLDR
A review of literature was performed on the etiopathogenesis of aggressive posterior retinopathy of prematurity (APROP), the characteristic and atypical clinical features, management strategies, anatomical and visual outcomes, and a multifaceted rational and individualized treatment strategy for APROP. Expand
Intravitreal Anti-Vascular Endothelial Growth Factor Injection versus Laser Photocoagulation for Retinopathy of Prematurity: A Meta-Analysis of 3701 Eyes.
TLDR
LPC had a lower likelihood of requiring additional treatment, while IVIs were associated with a longer interval from treatment to retreatment or recurrence, reduced risk of surgical intervention and superior refractive outcomes. Expand
Evaluation of Treatment Models in the Treatment of Retinopathy of Prematurity
TLDR
Intravitreal bevacizumab alone or combination with LPC is a highly effective treatment option for zone 1 disease and APROP, and IVB reduces the number of ROP treatments. Expand
Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP
TLDR
Evaluation of vascular leakage and retinal vascular development with fundus fluorescein angiography for infants diagnosed with aggressive posterior retinopathy of prematurity who underwent intravitreal anti-VEGF treatment found that early intervention with laser photocoagulation in early stages becomes possible enabling prevention of possible blindness. Expand
Aggressive Posterior Retinopathy of Prematurity (APROP): LASER as the Primary Modality of Treatment
Abstract Purpose To study the success rate of LASER as a primary modality of treatment in aggressive posterior retinopathy of prematurity (APROP) cases. Methods This is a prospective case series ofExpand
Treatment outcomes of combination of anti-vascular endothelial growth factor injection and laser photocoagulation in Type 1 ROP and APROP
To study treatment outcomes of combination treatment of intravitreal anti-vascular endothelial growth factor (VEGF) injection and laser photocoagulation in Type 1 Retinopathy of Prematurity (ROP) andExpand
...
1
2
...

References

SHOWING 1-10 OF 74 REFERENCES
Treatment of type 1 retinopathy of prematurity with bevacizumab versus laser.
TLDR
Both treatments resulted in good structural outcome, and no difference in visual acuity or refraction, however, more frequent follow-up was observed in the IVB group. Expand
Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity
TLDR
The regression of retinopathy of prematurity after one intravitreal injection of bevacizumab and the factors that influenced it was evaluated and no late retinal detachment was identified. Expand
LONG-TERM EFFECT OF ANTIANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY Up to 5 Years of Follow-up
TLDR
Five years of follow-up in a small series suggest that intravitreal bevacizumab for retinopathy of prematurity results in apparently preserved ocular function and systemic development. Expand
Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity.
TLDR
Intravitreal bevacizumab monotherapy, as compared with conventional laser therapy, in infants with stage 3+ retinopathy of prematurity showed a significant benefit for zone I but not zone II disease, and conventional laser Therapy led to permanent destruction of the peripheral retina. Expand
Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
TLDR
Both IVB and PRP are effective treatment options for type 1 ROP with low complication rates and IVB was associated with less myopia than PRP, although longer follow-up was available for PRP. Expand
Bevacizumab versus diode laser in stage 3 posterior retinopathy of prematurity
TLDR
There was a significant time delay to recurrence in the bevacizumab group compared with laser, with a mean age of 51 weeks PMA at time of recurrence as well as resolution of plus disease and flattening of the ridge by 48 hr postinjection in all eyes. Expand
Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings.
TLDR
This study documents significant vascular and macular abnormalities of eyes in the bevacizumab group and long-lasting implications of these abnormalities for visual function of the child need to be studied. Expand
Preliminary Anatomical and Neurodevelopmental Outcomes of Intravitreal Bevacizumab As Adjunctive Treatment for Retinopathy of Prematurity
TLDR
This pilot study indicates that IVB seems to contribute no further complications to the complications already present due to prematurity, and appears to be useful for advanced ROP when laser treatment is precluded or not sufficient for preventing the progression of ROP. Expand
Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian Twin Cities Retinopathy of Prematurity Screening database Report number 5
TLDR
Though intraocular bevacizumab, along with laser and surgery salvaged vision in many otherwise progressive cases of ROP, vigilance and reporting of serious adverse events is essential for future rationalised use of the drug. Expand
[Off-label use of intravitreal bevacizumab for severe retinopathy of prematurity].
TLDR
This report found no significant differences in the recurrence rates of ROP stage 3+ in zone II in patients treated with intravitreal bevacizumab monotherapy in comparison to láser, although the latter is the best option due to long-term safety and efficacy. Expand
...
1
2
3
4
5
...